Sidra Medicine Advances Innovation and Expands Precision Medicine Efforts
Doha, Qatar: In 2024, Sidra Medicine achieved remarkable advancements in healthcare, including providing life-saving care for over 230 injured children from Gaza and pioneering the region's first high-risk caesarean section in an angiography suite. The hospital also made significant progress in gene therapy and precision medicine.
Looking ahead to 2025, Sidra Medicine plans to expand its clinical trials programme, focusing on personalised treatments for the Arab population, a group historically underrepresented in medical research. This initiative has attracted partnerships with major pharmaceutical companies, highlighting the institution's commitment to advancing healthcare for the Arab population.
Dr. Iyabo Tinubu-Karch, Chief Executive Officer at Sidra Medicine, outlined the hospital's strategic goals for 2025, emphasizing the importance of advancing research and innovation, particularly in precision medicine and gene therapy for rare diseases. The hospital also aims to enhance digital health capabilities and continue pioneering groundbreaking research in genomics.
Sidra Medicine is committed to elevating women's and paediatric care, advancing gene therapies for conditions such as rare genetic disorders, childhood cancers, and inherited diseases. The hospital is also pioneering the use of interventional radiology, offering patients faster recovery times and less discomfort.
In alignment with Qatar’s Third National Development Strategy (NDS3) and Qatar National Vision 2030, Sidra Medicine is enhancing healthcare quality and expanding access to advanced medical services for women and children. The hospital's achievements in 2024 include administering Elevidys, a groundbreaking gene therapy for Duchenne Muscular Dystrophy (DMD), and launching a pioneering clinical trials program focused on the Arab population. Additionally, Sidra Medicine implemented clinical-grade Whole Genome Sequencing (WGS), significantly reducing diagnostic times for critically ill paediatric patients.
Sidra Medicine also achieved a landmark with a groundbreaking study on Inherited Metabolic Disorders (IMDs) in collaboration with the Qatar Precision Health Institute (QPHI), published in Genetics in Medicine. The study analysed genetic data from over 14,000 Qatar participants, enabling more targeted screenings and personalised treatments. Furthermore, the hospital launched Qatar’s only cord blood bank, providing families with local access to stem cell storage for future health treatments.